Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AxIn study of axitinib intensification plus nivolumab versus nivolumab alone after nivolumab + ipilimumab induction in metastatic renal cell carcinoma
2022-001150-35Phase 2Active
- Sponsor
- Consorzio Oncotech
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of axitinib, nivolumab and ipilimumab in renal cell carcinoma (RCC) (2 arms), sponsored by Consorzio Oncotech. Primary endpoint: Overall response rate. Started Sep 2022; status: active.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2022-001150-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001150-35.